Printer Friendly

ISIS SCIENTISTS PUBLISH PRECLINICAL DATA ON ISIS 2105 FOR GENITAL WARTS

 CARLSBAD, Calif., Feb. 17 /PRNewswire/ -- Scientists at Isis Pharmaceuticals, Inc. (NASDAQ: ISIP) have published preclinical data on the company's lead product, ISIS 2105. The drug is an antisense oligonucleotide and is currently in pivotal Phase II trials for the treatment of genital warts. The preclinical results appeared in the February issue of "Antimicrobial Agents and Chemotherapy" (Vol. 37:171- 177, 1993) and was authored by Lex M. Cowsert, Ph.D., et al.
 Genital warts are caused by the human papillomavirus (HPV), the fastest spreading, sexually-transmitted disease of viral origin in the world. Available treatments are non-specific and are based on surgical or chemical removal of the wart. These therapies do not remove the adjacent tissue which may be latently infected with HPV. Thus, recurrence rates of genital warts after treatment can be in excess of 60 percent due to latent infections.
 The development of specific anti-viral drugs against HPV has been hampered by the lack of appropriate cell and animal models. HPV normally cannot be grown in the laboratory or in animals. Isis scientists therefore devised a model based on related bovine virus which is more readily adapted to the laboratory setting. After determining the appropriate antisense target in the bovine virus, the Isis scientists devised a similar model for HPV which resulted in the identification of the antisense drug, ISIS 2105. ISIS 2105 is the first oligonucleotide to enter advanced stage testing in humans.
 The data published in the recent journal article, along with the appropriate toxicity and pharmacokinetic studies, were used by Isis to support the company's Investigational New Drug application on ISIS 2105. "The importance for new drug development of the preclinical models described in this publication is clear from the rapid progress of ISIS 2105 into human trials," said Dr. Stanley T. Crooke, chairman and chief executive officer of Isis.
 Isis Pharmaceuticals, based in northern San Diego County, is engaged in the discovery, development and marketing of novel human therapeutic products based on proprietary oligonucleotides. Isis has a broad oligonucleotide research program, has multiple compounds in preclinical development and its first oligonucleotide-based drug, ISIS 2105, is in Phase II clinical trials.
 -0- 2/17/93
 /CONTACT: Jacqueline G. Siegel, Ph.D., or Christopher K. Mirabelli, Ph.D., both of Isis Pharmaceuticals, Inc., 619-931-9200, or Anthony J. Russo, Ph.D., of Noonan-Russo Communications, 212-979-9180, for Isis Pharmaceuticals, Inc./
 (ISIP)


CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU:

TM-LD -- NY006 -- 7101 02/17/93 07:45 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 17, 1993
Words:410
Previous Article:$500 MILLION TO BE CUT FROM STATE BUDGET
Next Article:MEDICAL TECHNOLOGY SYSTEMS REPORTS NET INCOME INCREASED 36 PERCENT FOR QUARTER & 61 PERCENT FOR THE NINE MONTHS
Topics:


Related Articles
ISIS FILES WITH FDA TO BEGIN CLINICAL TRIALS OF ANTISENSE DRUG; FIRST ANTISENSE COMPOUND TO BE INJECTED INTO HUMANS
ISIS COMPLETES NORMAL SUBJECT STUDY AND INITIATES TRIALS IN PATIENTS WITH ITS FIRST ANTISENSE DRUG
ISIS SCIENTISTS PUBLISH PRECLINICAL DATA ON ISIS 2105 FOR GENITAL WARTS
ISIS ANNOUNCES PHASE I CLINICAL TRIAL RESULTS ON ISIS 2105
ISIS ANNOUNCES THE ISSUANCE OF A HERPES SIMPLEX OLIGONUCLEOTIDE PATENT
ISIS ANNOUNCES INITIATION OF CLINICAL TRIALS FOR ANTISENSE DRUG TO TREAT CMV INFECTIONS THAT CAUSE BLINDNESS IN AIDS PATIENTS
ISIS PHARMACEUTICALS COMMENCES CLINICAL TRIALS FOR ANTISENSE DRUG TO INHIBIT ICAM-1
NOVEL ANTI-HIV COMPOUND FROM ISIS PHARMACEUTICALS INHIBITS VIRAL REPLICATION IN VIVO
ISIS INITIATES PHASE II CLINICAL TRIALS OF ISIS 2302, AN ANTISENSE COMPOUND TO TREAT INFLAMMATORY DISEASES
ISIS ANNOUNCES RESULTS OF PILOT PHASE II CLINICAL TRIAL OF GENITAL WART COMPOUND AND DECISION NOT TO PURSUE FURTHER DEVELOPMENT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters